Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators
Kronos buys Gilead’s portfolio of SYK inhibitors, carrying the preclinical cancer play to the cusp of Phase III
New biomarker data for a clinical cancer therapy discontinued by Gilead prompted Kronos President and CEO Norbert Bischofberger to close a deal with his old company to bring the IP in-house to Kronos. The acquisition transforms Kronos from a company on the cusp of entering the clinic to one with a Phase III-ready asset while further cementing its focus on the transcription network.
Kronos Bio Inc. purchased the entire patent portfolio of SYK inhibitors from Gilead Sciences Inc. (NASDAQ:GILD) for an